MediciNova initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of MediciNova (MNOV) with a Buy rating and $10 price target MediciNova is a clinical-stage biotechnology company developing multi-target small molecule therapies across a broad pipeline, primarily focused on neurodegenerative and metabolic/fibrotic diseases with significant unmet medical need, the analyst tells investors in a research note. The firm says the company is well positioned to achieve favorable data-driven clinical milestones.